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Abstract: Combination of existing antibiotics have been introduced to increase the efficacy for a long time. Synergistic 
combinations of antibiotics are most desirable due to reduction of doses, toxicity and side effects of the individual 
antibiotic as well as prolonging in evolution of antibiotic resistance. Recently, antimicrobial peptides (AMPs) are gaining 
attention as viable alternatives to antibiotics due to the broad spectrum of activities and abundantly present in 
multicellular organisms that act against invading microbes. The combination of AMPs and conventional antibiotics 
enables to reduce the overall cost and widen the power of synergistic effects. Synergistic combinations are also reported 
among AMPs. Despite enormous advantages of synergistic combinations and several reports and uses in clinical 
medicine, only few underlying mechanisms are revealed. In this review, we overviewed the mechanisms of antimicrobial 
agents’ synergistic combinations and introduced the proteome chip approach for predicting new synergistic combinations 
and deciphering the synergy mechanisms. 
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INTRODUCTION 
Discovery and development of different antibiotics in 
past has revolutionized clinical medicine. Soon the 
magic bullets were followed by the emergence of 
resistance microbes. The condition is getting worst 
day-by-day due to rapid evolution of multidrug-resistant 
microbes, causing serious impact on human morbidity. 
Moreover, antibiotics cause collateral damage to 
commensal microbes and activate immune response 
leading to increase atopic and autoimmune disease [1].  
Several solutions are currently investigated to 
address above problems. One approach is through 
combination strategy for exploiting the full potential of 
existing antibiotics. Another is to search for the 
potential natural antimicrobial agents like antimicrobial 
peptides(AMPs) that can boost existing antibiotic power 
or directly have lethal action against pathogenic 
microbes. AMPs are usually cationic peptides of 
organisms acting against invading microbes (primary 
defense). In this review, we will explore the potential of 
synergistic combinations between antibiotic-antibiotic, 
antibiotic-AMP and AMP-AMP. Moreover, we have 
focused on the mechanism of actions of synergistic 
combinations. 
ANTIBIOTIC-ANTIBIOTIC COMBINATIONS 
Combinational therapy is a multi-beneficial 
approaches supported by clinical successes in past few 
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decades [2-4]. Drug combinations can be additive, 
synergistic or antagonistic depending on their 
combined effect being equal to, greater than or less 
than that of the expected value based on their 
individual effects [5,6]. The notable advantage 
achieved through the combination of antibiotics is the 
synergistic effects which reduce doses, toxicity and 
side effects of the individual antibiotic as well as delay 
in evolution of antibiotic resistance [7-9]. Due to these 
features, research has been intensively focused on fin- 
ding synergetic drug combinations. Table 1 summarize 
the synergistic antibiotic pairs and their mechanism of 
action against specific microbes.  
Although many synergistic combinations have been 
reported, only a few of their mechanisms are known. 
Understanding the synergistic mechanisms of 
combinational antimicrobial therapy can increase the 
therapeutic efficacy and reduce its unwanted use. In 
principle, synergistic mechanism behind some 
antimicrobial combination is relatively simple through 
physicochemical effects: where one drug facilitates the 
bioavailability of other drug [10]. For example, 
streptomycin and penicillin combination [11], 
gentamicin and vancomycin combination [12] and, 
erythromycin and penicillin combination [13], in which 
penicillin and vancomycin targets the cell envelope to 
increase the permeability for the entry of streptomycin, 
gentamicin and erythromycin inside the cell. Whereas 
streptomycin, gentamicin and erythromycin target on 
bacterial ribosome, causing misreading of the genetic 
code and inhibits translocation to disrupt protein 
synthesis. Figure 1 depicts the mechanisms of 
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synergistic combination, in which one antibiotic 
facilitates the entry of other antibiotic inside the cell. 
Another interesting synergistic mechanism drew our 
attention: dual inhibition on the same pathway. 
Trimethoprim and sulfonamides attacks FolA and FolP 
in folic acid biosynthesis pathway, respectively [14]. 
This dual inhibition on the same pathway causes great 
synergistic effect. Similarly, if the combinations of the 
multiple antimicrobial treatments target the proteins 
with the same function (redundant proteins) or 
pathways with the same function (related pathways), it 
Table 1: Synergistic Combinations and their Mechanisms of Action Against Microbes 
Synergistic Antibiotic Combination Mechanism of Action Coverage Against  
Penicillin and Streptomycin facilitate uptake of Streptomycin Streptococcus viridans 
Vancomycin and Gentamicin facilitate uptake of Gentamicin penicillin-resistant pneumococci 
Penicillin and Erythromycin facilitate uptake of Erythromycin - 
Trimethoprim and Sulfamethoxazole 
both target on same pathway  
(Folic acid pathway) 
E.coli, Shigella, Yersinia enterocolitics, Pneumocystis carinii 
Ampicillin and Dicloxacillin 
both target on same protein  
(Penicillin binding protein) 
Gram –negative infection 
 
Quinupristin and Dalfopristin 
both target on same protein 
(Exit channel in 50s ribosomal unit) 
Straphylococci, Vancomycin resistance Enterococcus faecium 
Tetracycline and Streptomycin Unknown Brucella, Yersinia pestis, Pseudomonas mallei 
Tetracycline and Chloramphenical Unknown Pseudomonas paeudomallei 
Isoniazid and Rifampin/Ethambutol Unknown Mycobacterium tuberculosis 
Dapsone and Rifampin Unknown Mycobacterium leprae 
Sulfonamide and Tetracycline Unknown Chlamydia trachomatis 
Erythromycin and Doxycycline Unknown  - 
Gentamicin and Ciprofloxacin  Unknown - 
 
 
Figure 1: Schematic diagram showing the mechanism of action of synergistic antibiotic combination. Most common 
mechanism is that one antibiotic facilitates the entry of other antibiotics. After the entry inside the cell, the other antibiotic act on 
intracellular target and kill the cell. Penicillin and Vancomycin targets on bacterial cell wall and facilitate the entry of 
Erythromycin, Streptomycin and Gentamicin. After entry inside the cell, Erythromycin target on the 50s subunit of ribosomes 
whereas Streptomycin and Gentamicin targets on the 30s subunits of ribosomes. 
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would also cause a synergistic effect because both 
main and alternative proteins or pathways would be 
disabled. 
AMP-ANTIBIOTIC AND AMP-AMP COMBINATIONS 
To further expand the scope of treatment, along 
with antibiotics combination, combination with natural 
antimicrobial peptides (AMPs) have been tried [15-19]. 
AMPs are usually cationic and amphiphilic. AMPs have 
been isolated from bacteria, fungi, plants and animal 
including human. AMPs are mostly gene encoded 
peptides initially synthesized as pre-pro-peptides which 
after cleavage of per- and pro-segment from N-terminal 
become fully functional [20]. These short chain 
peptides are active against Gram-positive and Gram-
negative bacteria, fungi, protozoa, parasites, cancer 
cells and also viruses [21, 22].  
AMPs exert multiple modes of action which can be 
categorized into two types: membrane lysis and no-
membrane lysis (intracellular targets) [23]. Usually, 
dual mechanisms are reported for several AMPs and 
are concentration dependent. AMPs cause membrane 
lysis at high concentration and no-membrane lysis at 
low concentration [24]. Moreover, wide spectrum, 
selective target, lower toxicity and diverse mechanism 
of action make AMPs an ideal candidate as future 
medicine [25].  
Recently, AMPs were reported to boost the 
activities of antibiotics with a great synergistic effect 
[16, 18, 19]. Thus, a new hope has emerged for fighting 
the battle by combining conventional antibiotics with 
AMPs. Table 2 summarize the synergistic combinations 
between AMP-AMP and AMP-antibiotic. 
Table 2: Summary Table of Reported AMPs and 
Antibiotics Combinations 
AMPs and Antibiotics Combination References 
Lactoferricin B + PR-39 Ho et al (2016) 
Lactoferricin B + Bac7 Ho et al (2016) 
Tachyplesin I + Magainin Kobayashi et al (2001) 
apidaecin + Magainin II Fieck et al (2010) 
Indolicidin + Protegrin 1 Yan and Hancock (2001) 
Human neutrophil defensin-1 + 
Vancomycin Yeaman et al (1992) 
Buforin II + Minocycline Giacometti et al (2000) 
Tritrpticin + Ceftazidime Cirioni et al (2006) 
Cryptin-2 + Amplicillin Rishi et al (2011) 
Nisin Z + Ampicillin; Streptomycin Naghmouchi et al (2012) 
Nisin Z + Streptomycin Naghmouchi et al (2012) 
 
MECHANISM BASED ON TARGET ANALYSIS 
Target analysis would be a good approach to 
explore the synergistic mechanisms in antimicrobial 
combinations. By analyzing the targets of the 
antibiotics or AMPs, it will allow us not only to decipher 
synergistic mechanisms of the known combinations but 
also to predict synergistic combinations. In past, 
exploring the underlying synergistic combinations was 
labor-intensive, time consuming trial-and-error 
experiments. Target analysis will provide an effective 
 
Figure 2: Schematic diagram of the identification of protein targets of AMPs by using E. coli proteome microarray 
assay. To identify the proteins targets AMPs, E. coli proteome chips were incubated with biotinylated AMPs. DyLight labeled 
streptavidin was then probed with chips to identify the targets of individual AMPs. DyLight labeled anti-His antibody was used to 
detect the relative amount of the proteins.  
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design of synergistic combinations. Xu [26] also 
reported that the targets of drugs are important 
elements for the development of effective drug 
combinations. However, the targets of AMPs and 
antibiotics were not comprehensively investigated and 
analyzed. Usually, only one or two targets are known 
for an antibiotic, which is not enough to analyze or 
predict their synergistic mechanism. 
In our Lab, we have developed a method for the 
systematical and comprehensive identification of all the 
targets of AMPs and antibiotics through proteome 
microarrays. Proteome microarray is an excellent tool 
which provides a high-throughput and rapid platform for 
the identifications of protein targets. Figure 2 depicts 
the schematic diagram of probing biotinylated AMPs on 
E. coli proteome microarray, comprise of ~42,000 
proteins, purified and probed individually on the glass 
slide coated with aldehyde. DyLight labeled streptavidin 
and DyLight labeled anti-His antibody were probed to 
identify the targets of individual biotinylated AMPs and 
detect the relative amount of the proteins on the E. coli 
proteome microarray, respectively. In our previous 
work, E. coli proteome microarrays were applied to 
identify the targets of Lactoferricin B (Lfcin B), found in 
human gut from the digestion of bovine milk. Our study 
suggested that Lfcin B influenced the metabolic 
process via multiple protein targets [27]. 
The proteome targets of AMPs: bactenecin 7  
(Bac 7), a hybrid of Pleurocidin and Dermaseptin (P-
Der) and a proline-arginine-rich antibacterial peptide 
(PR-39) were also identified by using E. coli proteome 
microarrays [28]. The comprehensive analysis of the 
protein targets of four AMPs (LfcinB, Bac7, P-Der and 
PR-39) showed common enrichment in the same 
pathway. Purine metabolism was enriched in both Lfcin 
B and Bac7. Lipopolysaccharide (LPS) biosynthesis 
was enriched in both Lfcin B and PR-39. This result 
showed the possibility of synergy between Lfcin B and 
Bac7 and also Lfcin B and PR-39. To validate this 
prediction, the synergistic combination between Lfcin B 
and Bac7 as well as Lfcin B and PR-39 were 
experimentally tested in vivo. Figure 3 (A and B) shows 
the growth inhibition by individual and combined AMPs 
on E. coli MG1655 at 7.33 hours. Significant 
differences in cell growth were observed between 
expected and experimental combination of AMPs. The 
 
Figure 3: Treatment of different AMPs on E. coli MG1655 and the growth recorded after 7.33 hr. A. the growth inhibition 
by individual and combined Lfcin B and PR-39. B. the growth inhibition by individual and combined Bac7 and Lfcin B. Expected 
value is calculated by the inhibition of one AMP upon the other AMP individually. 
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expected value was calculated by the individual 
inhibitory effect of two AMPs in turns. The experimental 
result of combined Lfcin B and PR-39 shows 
significantly greater inhibitory effect than the expected 
value calculated by the Lfcin Bupon PR-39 individual 
inhibitory effect. This result indicates a synergy 
between Lfcin B and PR-39 (Figure 3A). Similarly, Bac 
7 and Lfcin B is a synergistic pair due to the much 
higher effect of combined treatment of Bac 7 and Lfcin 
B than the expected value obtained from the individual 
Bac 7 and Lfcin B inhibitory effect (Figure 3B). Thus, 
the growth inhibition assay successfully validated the 
predictions of the new synergistic combination pairs 
and also deciphered the mechanism of synergistic 
combination based on the focused damage of most 
proteins on a pathway [28]. These results indicated the 
importance to identify all the targets of individual 
antimicrobial agents comprehensively and thoroughly 
for the investigation of synergistic effect. 
CONCLUSION 
In summary, synergistic combinations have proved 
to be the powerful therapy which can overcome the 
disadvantage of individual antimicrobial reagent and 
provide new options against pathogens. More 
researches should be carried out to discover new 
synergistic combination. To use the combinational 
therapy more specifically, we also need to explore the 
mechanisms involve in synergistic combinations. The 
mechanisms of synergistic combinations are much 
more complicated than it was previously explained with 
a single target molecule of an antimicrobial reagent. 
Our proteome microarray approach has provided a 
platform for systematical and comprehensive identifica- 
tion of AMP targets. Target analysis enables precisely 
prediction of a new synergistic combination and 
explains the mechanism of synergistic combinations. In 
future, we will keep analyzing more AMPs and 
antibiotics to predict more combinations and decipher 
the mechanism of synergistic combinations. The new 
synergistic combinations with fully explained 
mechanism will be powerful weapons in the war of the 
mankind against pathogens.  
CONFLICT OF INTEREST 
The authors declare that there are no conflicts of 
interest 
ACKNOWLEDGEMENTS 
The authors gratefully acknowledge financial 
support from Taiwan Ministry of Science and 
Technology grant MOST 104-2320-B-008-002-MY3 
AND Veterans General Hospitals and University 
System of Taiwan VGHUST 106-G1-4-2. 
REFERENCES  
[1] Blaser M. Antibiotic overuse: Stop the killing of beneficial 
bacteria. Nature 2011; 476: 393-394. 
https://doi.org/10.1038/476393a 
[2] Gupta EK, Ito MK. Lovastatin and extended-release niacin 
combination product: the first drug combination for the 
management of hyperlipidemia. Heart disease 2002; 4: 124-
137. 
https://doi.org/10.1097/00132580-200203000-00010 
[3] Larder BA, Kemp SD, Harrigan PR. Potential mechanism for 
sustained antiretroviral efficacy of AZT-3TC combination 
therapy. Science 1995; 269: 696-699. 
https://doi.org/10.1126/science.7542804 
[4] Zimmermann GR, Lehar J, Keith CT. Multi-target 
therapeutics: when the whole is greater than the sum of the 
parts. Drug discovery today 2007; 12: 34-42. 
https://doi.org/10.1016/j.drudis.2006.11.008 
[5] Loewe S. The problem of synergism and antagonism of 
combined drugs. Arzneimittel-Forschung 1953; 3: 285-290. 
[6] Chou TC. Drug combination studies and their synergy 
quantification using the Chou-Talalay method. Cancer 
research 2010; 70: 440-446. 
https://doi.org/10.1158/0008-5472.CAN-09-1947 
[7] Cokol M, Chua HN, Tasan M, Mutlu B et al., Systematic 
exploration of synergistic drug pairs. Molecular systems 
biology 2011; 7: 544. 
https://doi.org/10.1038/msb.2011.71 
[8] Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R. 
Accelerated evolution of resistance in multidrug 
environments. Proceedings of the National Academy of 
Sciences of the United States of America 2008; 105: 13977-
13981. 
https://doi.org/10.1073/pnas.0805965105 
[9] Lehar J, Krueger AS, Avery W, Heilbut AM et al., Synergistic 
drug combinations tend to improve therapeutically relevant 
selectivity. Nature biotechnology 2009; 27: 659-666. 
https://doi.org/10.1038/nbt.1549 
[10] Davis BD. Mechanism of bactericidal action of 
aminoglycosides. Microbiological reviews 1987; 51: 341-350. 
[11] Plotz PH, Davis BD. Synergism between streptomycin and 
penicillin: a proposed mechanism. Science 1962; 135: 1067-
1068. 
https://doi.org/10.1126/science.135.3508.1067 
[12] Cottagnoud P, Cottagnoud M, Tauber MG. Vancomycin acts 
synergistically with gentamicin against penicillin-resistant 
pneumococci by increasing the intracellular penetration of 
gentamicin. Antimicrobial agents and chemotherapy 2003; 
47: 144-147. 
https://doi.org/10.1128/AAC.47.1.144-147.2003 
[13] Dinos GP, Connell SR, Nierhaus KH, Kalpaxis DL, 
Erythromycin roxithromycin, and clarithromycin: use of slow-
binding kinetics to compare their in vitro interaction with a 
bacterial ribosomal complex active in peptide bond formation. 
Molecular pharmacology 2003; 63: 617-623. 
https://doi.org/10.1124/mol.63.3.617 
[14] Nichols RJ, Sen S, Choo YJ, Beltrao P, et al., Phenotypic 
landscape of a bacterial cell. Cell 2011; 144: 143-156. 
https://doi.org/10.1016/j.cell.2010.11.052 
[15] Bahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals 
2013: 6: 1543-1575. 
https://doi.org/10.3390/ph6121543 
 
Combinational Synergy of Antibiotics and Antimicrobial Peptides Journal of Translational Proteomics Research, 2017, Vol. 3    11 
[16] Brumfitt W, Salton MR, Hamilton-Miller JM, Nisin alone and 
combined with peptidoglycan-modulating antibiotics: activity 
against methicillin-resistant Staphylococcus aureus and 
vancomycin-resistant enterococci. The Journal of 
antimicrobial chemotherapy 2002; 50: 731-734. 
https://doi.org/10.1093/jac/dkf190 
[17] Hancock RE, Sahl HG. Antimicrobial and host-defense 
peptides as new anti-infective therapeutic strategies. Nature 
biotechnology 2006; 24: 1551-1557. 
https://doi.org/10.1038/nbt1267 
[18] McCafferty DG, Cudic P, Yu MK, Behenna DC, Kruger R. 
Synergy and duality in peptide antibiotic mechanisms. 
Current opinion in chemical biology 1999; 3: 672-680. 
https://doi.org/10.1016/S1367-5931(99)00025-3 
[19] Naghmouchi K, Le Lay C, Baah J, Drider D. Antibiotic and 
antimicrobial peptide combinations: synergistic inhibition of 
Pseudomonas fluorescens and antibiotic-resistant variants. 
Research in microbiology 2012; 163: 101-108. 
https://doi.org/10.1016/j.resmic.2011.11.002 
[20] Bals R. Epithelial antimicrobial peptides in host defense 
against infection. Respir Res 2000; 1: 141-150. 
https://doi.org/10.1186/rr25 
[21] Pushpanathan M, Gunasekaran P, Rajendhran J. 
Antimicrobial peptides: versatile biological properties. Int J 
Pept 2013; 2013: 675391. 
https://doi.org/10.1155/2013/675391 
[22] Zasloff M, Antimicrobial peptides of multicellular organisms. 
Nature 2002; 415: 389-395. 
https://doi.org/10.1038/415389a 
[23] Shah P, Hsiao FS, Ho YH, Chen CS. The proteome targets 
of intracellular targeting antimicrobial peptides. Proteomics 
2016; 16: 1225-1237. 
https://doi.org/10.1002/pmic.201500380 
[24] Cudic M, Otvos L. Intracellular targets of antibacterial 
peptides. Curr Drug Targets 2002; 3: 101-106. 
https://doi.org/10.2174/1389450024605445 
[25] Hancock RE, Patrzykat A. Clinical development of cationic 
antimicrobial peptides: from natural to novel antibiotics. Curr 
Drug Targets Infect Disord 2002; 2: 79-83. 
https://doi.org/10.2174/1568005024605855 
[26] Xu KJ, Song J, Zhao XM. The drug cocktail network. BMC 
systems biology 2012; 6 Suppl 1: S5. 
https://doi.org/10.1186/1752-0509-6-S1-S5 
[27] Tu YH, Ho YH, Chuang YC, Chen PC, Chen CS. 
Identification of lactoferricin B intracellular targets using an 
Escherichia coli proteome chip. PloS one 2011; 6: e28197. 
https://doi.org/10.1371/journal.pone.0028197 
[28] Ho YH, Shah P, Chen YW, Chen CS. Systematic Analysis of 
Intracellular-targeting Antimicrobial Peptides, Bactenecin 7, 
Hybrid of Pleurocidin and Dermaseptin, Proline-Arginine-rich 
Peptide, and Lactoferricin B, by Using Escherichia coli 
Proteome Microarrays. Molecular & cellular proteomics: MCP 
2016; 15: 1837-1847. 
https://doi.org/10.1074/mcp.M115.054999 
 
 
 
Received on 09-05-2017 Accepted on 08-06-2017 Published on 07-07-2017 
 
http://dx.doi.org/10.15379/2410-3802.2017.03.02 
© 2017 Shah and Chen; Licensee Cosmos Scholars Publishing House. 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, 
provided the work is properly cited. 
 
